Pathophysiological review explores platelet activity and antiplatelet agents in metabolic dysfunction-associated steatohepatitis and steatotic liver disease.

This publication is a pathophysiological review focusing on metabolic dysfunction-associated steatohepatitis and metabolic dysfunction-associated steatotic liver disease. The authors investigate the relationship between platelet activity and liver pathology, specifically considering the use of antiplatelet agents as a potential therapeutic strategy. The scope encompasses molecular interactions between platelets and the liver rather than a specific clinical trial design.

The review discusses secondary outcomes including disease severity, inflammatory activity, fibrotic progression, unfavorable clinical outcomes, hepatic inflammation, cellular injury, fibrosis, progression to cirrhosis, and progression to hepatocellular carcinoma. However, the main results field is empty, indicating no specific pooled effect sizes or quantitative data were synthesized in this text. The authors highlight the biological plausibility of targeting platelet activity but do not present definitive clinical efficacy metrics.

Significant limitations are acknowledged regarding the current state of evidence. The authors note that robust clinical evidence is still required to establish safety and effectiveness of antiplatelet agents. Furthermore, important gaps persist in understanding the molecular basis of platelet–liver interactions. Safety data regarding adverse events, serious adverse events, and discontinuations are not reported.

Clinicians should be cautious about overstating the encouraging potential of antiplatelet agents or the utility of platelet-related markers as non-invasive indicators. Without reported sample sizes, populations, or follow-up durations, the evidence remains theoretical. Practice relevance is not reported, suggesting these findings are primarily for hypothesis generation rather than immediate guideline implementation.